Literature DB >> 25813210

GPX2 underexpression indicates poor prognosis in patients with urothelial carcinomas of the upper urinary tract and urinary bladder.

I-Wei Chang1,2, Victor Chia-Hsiang Lin1,3, Chih-Hsin Hung1, Hua-Pin Wang3, Yung-Yao Lin3, Wen-Jeng Wu4,5,6, Chun-Nung Huang4,5,7, Ching-Chia Li4,5,7,8, Wei-Ming Li4,5,7, Jui-Yu Wu9, Chien-Feng Li10,11,12,13.   

Abstract

PURPOSE: Oxidative stress is believed to be one of the important etiologies in carcinogenesis that has not been systemically investigated in urothelial carcinoma (UC). Through data mining from a published transcriptomic database of UC of urinary bladders (UBUCs) (GSE31684), glutathione peroxidase 2 (GPX2) was identified as the most significant downregulated gene among those response to oxidative stress (GO:0006979). We therefore analyze GPX2 transcript and protein expressions and its clinicopathological significance.
METHODS: Real-time RT-PCR assay was used to detect GPX2 mRNA level in 20 fresh UBUC specimens. Immunohistochemistry was used to determine GPX2 protein expression in 340 urothelial carcinomas of upper tracts (UTUCs) and 295 UBUCs with mean/median follow-up of 44.7/38.9 and 30.8/23.1 months, respectively. Its expression status was further correlated with clinicopathological features and evaluated for its impact on disease-specific survival and metastasis-free survival (MeFS).
RESULTS: Decrease in GPX2 transcript level was associated with both higher pT and positive nodal status in 20 UBUCs (all p < 0.05). GPX2 protein underexpression was also significantly associated with advanced pT status, nodal metastasis, high histological grade, vascular invasion, and frequent mitoses in both groups of UCs (all p < 0.05). GPX2 underexpression not only predicted dismal DDS and MeFS at univariate analysis, but also implicated worse DDS (UTUC, p = 0.002; UBUC, p = 0.029) and MeFS (UTUC, p = 0.001; UBUC, p = 0.032) in multivariate analysis.
CONCLUSIONS: GPX2 underexpression is associated with advanced tumor status and implicated unfavorable clinical outcome of UCs, suggesting its role in tumor progression and may serve as a theranostic biomarker of UCs.

Entities:  

Keywords:  GPX2; Glutathione peroxidase 2; Prognosis; Urothelial carcinoma

Mesh:

Substances:

Year:  2015        PMID: 25813210     DOI: 10.1007/s00345-015-1522-7

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  37 in total

1.  Primary urothelial carcinoma of the upper tract: important clinicopathological factors predicting bladder recurrence after surgical resection.

Authors:  Wen-Wei Huang; Hsuan-Ying Huang; Alex C Liao; Yow-Ling Shiue; Hsiu-Lun Tai; Chun-Mao Lin; Yu-Hui Wang; Ching-Nan Lin; Kun-Hung Shen; Chien-Feng Li
Journal:  Pathol Int       Date:  2009-09       Impact factor: 2.534

2.  Smoking and cancer-related gene expression in bronchial epithelium and non-small-cell lung cancers.

Authors:  M Woenckhaus; L Klein-Hitpass; U Grepmeier; J Merk; M Pfeifer; Pj Wild; M Bettstetter; P Wuensch; H Blaszyk; A Hartmann; F Hofstaedter; W Dietmaier
Journal:  J Pathol       Date:  2006-10       Impact factor: 7.996

Review 3.  Role of oxygen radicals in DNA damage and cancer incidence.

Authors:  Marian Valko; Mario Izakovic; Milan Mazur; Christopher J Rhodes; Joshua Telser
Journal:  Mol Cell Biochem       Date:  2004-11       Impact factor: 3.396

4.  Altered antioxidant status and lipid peroxidation in Indian patients with urothelial bladder carcinoma.

Authors:  Nitika Badjatia; Abhigyan Satyam; Prabhjot Singh; Amlesh Seth; Alpana Sharma
Journal:  Urol Oncol       Date:  2009-01-26       Impact factor: 3.498

5.  Glutathione Peroxidase 2 Inhibits Cyclooxygenase-2-Mediated Migration and Invasion of HT-29 Adenocarcinoma Cells but Supports Their Growth as Tumors in Nude Mice.

Authors:  Antje Banning; Anna Kipp; Stephanie Schmitmeier; Maria Löwinger; Simone Florian; Susanne Krehl; Sophie Thalmann; René Thierbach; Pablo Steinberg; Regina Brigelius-Flohé
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

6.  Expression profiling and genetic alterations of the selenoproteins GI-GPx and SePP in colorectal carcinogenesis.

Authors:  Oliver Hatem Al-Taie; Nurcan Uceyler; Ursula Eubner; Franz Jakob; Hubert Mörk; Michael Scheurlen; Regina Brigelius-Flohe; Katrin Schöttker; Josef Abel; Andreas Thalheimer; Tiemo Katzenberger; Bertram Illert; Ralf Melcher; Josef Köhrle
Journal:  Nutr Cancer       Date:  2004       Impact factor: 2.900

7.  Evolutionary and structural insights into the multifaceted glutathione peroxidase (Gpx) superfamily.

Authors:  Stefano Toppo; Stefano Vanin; Valentina Bosello; Silvio C E Tosatto
Journal:  Antioxid Redox Signal       Date:  2008-09       Impact factor: 8.401

8.  Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes.

Authors:  Fong-Fong Chu; R Steven Esworthy; Peiguo G Chu; Jeffrey A Longmate; Mark M Huycke; Sharon Wilczynski; James H Doroshow
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

9.  Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.

Authors:  Yair Lotan; Aditya Bagrodia; Niccolo Passoni; Varun Rachakonda; Payal Kapur; Yull Arriaga; Christian Bolenz; Vitaly Margulis; Ganesh V Raj; Arthur I Sagalowsky; Shahrokh F Shariat
Journal:  Eur Urol       Date:  2013-04-03       Impact factor: 20.096

10.  Comparative gene expression profiling analysis of urothelial carcinoma of the renal pelvis and bladder.

Authors:  Zhongfa Zhang; Kyle A Furge; Ximing J Yang; Bin T Teh; Donna E Hansel
Journal:  BMC Med Genomics       Date:  2010-12-15       Impact factor: 3.063

View more
  15 in total

Review 1.  Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review.

Authors:  Aurélie Mbeutcha; Morgan Rouprêt; Ashish M Kamat; Pierre I Karakiewicz; Nathan Lawrentschuk; Giacomo Novara; Jay D Raman; Christian Seitz; Evanguelos Xylinas; Shahrokh F Shariat
Journal:  World J Urol       Date:  2016-04-21       Impact factor: 4.226

2.  VNN1 overexpression is associated with poor response to preoperative chemoradiotherapy and adverse prognosis in patients with rectal cancers.

Authors:  Chi-Yung Chai; Yimin Zhang; Junlong Song; Shih-Chun Lin; Shengrong Sun; I-Wei Chang
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

Review 3.  The beginning of GPX2 and 30 years later.

Authors:  R Steven Esworthy; James H Doroshow; Fong-Fong Chu
Journal:  Free Radic Biol Med       Date:  2022-07-05       Impact factor: 8.101

Review 4.  Selenoproteins and Metastasis.

Authors:  Michael P Marciel; Peter R Hoffmann
Journal:  Adv Cancer Res       Date:  2017-09-01       Impact factor: 6.242

5.  Prognostic Impact of Thrombospodin-2 (THBS2) Overexpression on Patients with Urothelial Carcinomas of Upper Urinary Tracts and Bladders.

Authors:  I-Wei Chang; Chien-Feng Li; Victor Chia-Hsiang Lin; Hong-Lin He; Per-In Liang; Wen-Jeng Wu; Ching-Chia Li; Chun-Nung Huang
Journal:  J Cancer       Date:  2016-07-08       Impact factor: 4.207

Review 6.  Predictive models and prognostic factors for upper tract urothelial carcinoma: a comprehensive review of the literature.

Authors:  Aurélie Mbeutcha; Romain Mathieu; Morgan Rouprêt; Kilian M Gust; Alberto Briganti; Pierre I Karakiewicz; Shahrokh F Shariat
Journal:  Transl Androl Urol       Date:  2016-10

7.  Complement Component 1, s Subcomponent Overexpression is an Independent Poor Prognostic Indicator in Patients with Urothelial Carcinomas of the Upper Urinary Tract and Urinary Bladder.

Authors:  I-Wei Chang; Victor Chia-Hsiang Lin; Wen-Jen Wu; Peir-In Liang; Wei-Ming Li; Bi-Wen Yeh; Hong-Lin He; Alex Chien-Hwa Liao; Ti-Chun Chan; Chien-Feng Li
Journal:  J Cancer       Date:  2016-06-30       Impact factor: 4.207

8.  DDR2 overexpression in urothelial carcinoma indicates an unfavorable prognosis: a large cohort study.

Authors:  Meng-Chen Tsai; Wei-Ming Li; Chun-Nung Huang; Hung-Lung Ke; Ching-Chia Li; Hsin-Chih Yeh; Ti-Chun Chan; Peir-In Liang; Bi-Wen Yeh; Wen-Jeng Wu; Sher-Wei Lim; Chien-Feng Li
Journal:  Oncotarget       Date:  2016-11-29

9.  GPX2 promotes development of bladder cancer with squamous cell differentiation through the control of apoptosis.

Authors:  Taku Naiki; Aya Naiki-Ito; Keitaro Iida; Toshiki Etani; Hiroyuki Kato; Shugo Suzuki; Yoriko Yamashita; Noriyasu Kawai; Takahiro Yasui; Satoru Takahashi
Journal:  Oncotarget       Date:  2018-03-23

10.  Reduced Expression Level of GPX2 in T1 Bladder Cancer and its Role in Early-phase Invasion of Bladder Cancer.

Authors:  Akinori Minato; Hirotsugu Noguchi; Rei Ohnishi; Ikko Tomisaki; Toshiyuki Nakayama; Naohiro Fujimoto
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.